Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor serum tumor marker reclassification petition to go before FDA panel.

This article was originally published in The Gray Sheet

Executive Summary

SERUM TUMOR MARKER DOWNCLASSIFICATION PETITION TO BE REVIEWED BY PANEL, FDA staffers say. The agency is planning a fall meeting of its Immunology Devices Panel to address a citizens petition recently submitted by Centocor seeking reclassification of serum tumor markers from their current Class III status to Class II. FDA had been planning a public workshop for this summer on the regulatory status of the devices; however, scheduling problems with possible participants and the submission of the Centocor petition convinced the agency that a panel meeting would be a more appropriate forum for discussion of the issue.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004170

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel